Beat Childhood Cancer offers phase I and phase II clinical trials to children battling childhood cancer. Our focus is on using precision medicine in patients at diagnosis as well as in difficult to treat relapsed and refractory cancers. Our goal is to increase survival and decrease toxicity while targeting the unique factors driving each child’s tumor.
NMTRC014NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO) OPENDifluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence. |
LEARN MORE | |
NMTRC012PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy OPENA prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma. |
LEARN MORE | |
ONC-403-001A Two-Part Study of TB-403 in Pediatric Subjects with Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma, or Alveolar Rhabdomyosarcoma. OPEN |
LEARN MORE | |
NMTRC011A Phase I Trial of Tolcapone and Oxaliplatin in Patients with Relapsed or Refractory Neuroblastoma OPEN |
LEARN MORE | |
V0706A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma OPEN TO THE FOLLOWING GROUPS: RELAPSE NEUROBLASTOMA MEDULLOBLASTOMA |
LEARN MORE | |
NMTRC010A Phase I/II Trial of DFMO in Combination with Bortezomib in Patients with Relapsed or Refractory Neuroblastoma COMPLETED |
LEARN MORE | |
NMTRC009Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers COMPLETED |
LEARN MORE | |
HITC001A Standardized Protocol of Surgery and Radiation for Patients with Brain Metastases in Relapsed Neuroblastoma A companion study to NMTRC009 COMPLETED |
LEARN MORE | |
NMTRC003BA Phase II Preventative Trial of DFMO as a Single Agent in Patients with High Risk Neuroblastoma in Remission COMPLETED |
LEARN MORE | |
NMTRCPG007A Phase II, Open-label, Multi-center, Pilot Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients with Refractory Pontine Glioma COMPLETED |
LEARN MORE | |
NMTRC002A Phase I Trial for Refractory or Relapsed Neuroblastoma with DFMO Along and in Combination with Etoposide COMPLETED |
LEARN MORE | |
NMTRC008A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancer COMPLETED |
LEARN MORE | |
NMTRC001A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma COMPLETED |
LEARN MORE | |
NMTRC001PA Pilot Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma CLOSED |
LEARN MORE | |
TPI-287-11A Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma COMPLETED |
LEARN MORE | |
NMTRC004A Phase I/II Trial of TPI 287 in Patients with Refractory or Recurrent Neuroblastoma and Medulloblastoma COMPLETED |
LEARN MORE | |
NMTRC005A Randomized, Phase I/II trial of Irinotecan and Temozolomide compared to Irinotecan and Temozolomide in Combination with TPI 287 in Patients with Primary Refractory or Early Relapsed Neuroblastoma COMPLETED |
LEARN MORE | |
V0610A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma COMPLETED |
LEARN MORE | |